Is Xenon Pharmaceuticals (XENE) Attractive After Recent Pullback And Strong One Year Rally

Simply Wall St.

Apr 25

Wondering if Xenon Pharmaceuticals at around US$55.24 is offering good value right now? This article walks through the numbers behind the price so you can judge for yourself. The stock has pulled back...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.gotigerhk.com/news/2630870174"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630870174\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630870174?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114","is_english":true,"pubTime":"2026-04-25 17:09","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630870174","market":"nz","top_or_hot":-1,"title":"Is Xenon Pharmaceuticals (XENE) Attractive After Recent Pullback And Strong One Year Rally","media":"Simply Wall St.","content":"<div>\n<p>Wondering if Xenon Pharmaceuticals at around US$55.24 is offering good value right now? This article walks through the numbers behind the price so you can judge for yourself. The stock has pulled back...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/is-xenon-pharmaceuticals-xene-attractive-after-recent-pullba\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Xenon Pharmaceuticals (XENE) Attractive After Recent Pullback And Strong One Year Rally</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Xenon Pharmaceuticals (XENE) Attractive After Recent Pullback And Strong One Year Rally\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-04-25 17:09 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/is-xenon-pharmaceuticals-xene-attractive-after-recent-pullba><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Wondering if Xenon Pharmaceuticals at around US$55.24 is offering good value right now? This article walks through the numbers behind the price so you can judge for yourself. The stock has pulled back...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/is-xenon-pharmaceuticals-xene-attractive-after-recent-pullba\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"DCF","symbol_name":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/is-xenon-pharmaceuticals-xene-attractive-after-recent-pullba","article_id":"2630870174","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice1-main-header/1585186710114"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-xene/xenon-pharmaceuticals/news/is-xenon-pharmaceuticals-xene-attractive-after-recent-pullba","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2630870174","pubTimestamp":1777108199,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Wondering if Xenon Pharmaceuticals at around US$55.24 is offering good value right now? This article walks through the numbers behind the price so you can judge for yourself.\nThe stock has pulled back 7.5% over the last week and is roughly flat over the past month. It still shows a 24.2% year to date return and 46.8% over the past year, which can change how investors think about both upside and risk.\nRecent attention on Xenon Pharmaceuticals has focused on its position within the...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","XENE":"Xenon制药","BK4139":"生物科技"},"translate_title":"Xenon Pharmaceuticals(XENE)在最近的回调和一年的强劲反弹之后是否有吸引力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"XENE":1.5,"DCF":1},"content_text":"Wondering if Xenon Pharmaceuticals at around US$55.24 is offering good value right now? This article walks through the numbers behind the price so you can judge for yourself. The stock has pulled back 7.5% over the last week and is roughly flat over the past month. It still shows a 24.2% year to date return and 46.8% over the past year, which can change how investors think about both upside and risk. Recent attention on Xenon Pharmaceuticals has focused on its position within the pharmaceuticals and biotech space and on how its share price performance compares with peers and broader sector sentiment. These factors help frame whether the current level reflects company specific expectations or a wider shift in how similar stocks are being priced. Xenon Pharmaceuticals currently has a value score of 4 out of 6. The next sections will walk through what that means across different valuation methods, before finishing with a way to pull all those valuation signals together more effectively.  Xenon Pharmaceuticals delivered 46.8% returns over the last year. See how this stacks up to the rest of the Biotechs industry. AdvertisementApproach 1: Xenon Pharmaceuticals Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes projected future cash flows, then discounts them back to today using a required rate of return to estimate what the business might be worth now. For Xenon Pharmaceuticals, the latest twelve month free cash flow is a loss of $288.609 million. Analysts provide free cash flow estimates out to 2030, with projections showing $336 million of free cash flow in 2030. The 2 Stage Free Cash Flow to Equity model then extends those analyst inputs with further extrapolated estimates provided by Simply Wall St. After discounting all those projected cash flows back to today, the model arrives at an estimated intrinsic value of about $303.98 per share. At a current share price around $55.24, this framework suggests the stock is 81.8% undervalued based purely on this DCF model. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Xenon Pharmaceuticals is undervalued by 81.8%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks. XENE Discounted Cash Flow as at Apr 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Xenon Pharmaceuticals. Approach 2: Xenon Pharmaceuticals Price vs Book For a company that is not yet profitable, earnings based metrics like the P/E ratio are less useful, so valuation often leans on balance sheet based measures such as price to book, or P/B. P/B compares the market value of the equity to the accounting value of net assets, which can be a practical anchor while the income statement is still loss making. Growth expectations and risk still matter here. A higher expected growth profile or lower perceived risk can justify paying more than book value, while slower growth or higher execution risk can point to a lower, more conservative P/B as a reasonable range. Xenon Pharmaceuticals currently trades on a P/B of 9.06x. The broader Biotechs industry average is around 2.34x, while a peer group sits closer to 21.04x. Simply Wall St also estimates a proprietary “Fair Ratio” for the preferred multiple, which blends in factors such as earnings growth outlook, profit margin structure, industry characteristics, market cap and company specific risks. This tailored Fair Ratio is designed to be more informative than a simple comparison with peers or the broad industry because it adjusts for these company level features. In this case, the Fair Ratio is not available, so it is not possible to classify the P/B as overvalued, undervalued or about right. Result: ABOUT RIGHT NasdaqGM:XENE P/B Ratio as at Apr 2026 P/B ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies. Upgrade Your Decision Making: Choose your Xenon Pharmaceuticals Narrative Earlier it was mentioned that there is an even better way to understand valuation. Narratives let you attach a clear story about Xenon Pharmaceuticals to the numbers by linking your view on its epilepsy, depression and pain pipeline to specific revenue, earnings and margin forecasts. These are then turned into a Fair Value that you can easily compare with the current price on Simply Wall St’s Community page. Narratives update as new earnings or trial news arrives. As a result, one investor might focus on a cautious view around a Fair Value near US$58.58, while another leans into a more optimistic story closer to US$100. You can quickly see where your own view sits on that spectrum. Do you think there's more to the story for Xenon Pharmaceuticals? Head over to our Community to see what others are saying! NasdaqGM:XENE 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}